

FIG. 1




FIG. 2




FIG. 3




FIG. 4





FIG. 5



Purified MBP (8 mg/L) is passively absorbed to microtitre plate

Diluted patient plasma is added to the wells

60 minutes, RT Incubation

Purified anti-human IgG/IgM-^{HRP} is added to the wells

60 minute, RT Incubation

TMB substrate is added to the wells

Incubate 2.5 minutes, RT dark

Reaction is stopped with 1N H₂SO₄

Optical Density is read at 450nm

0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

FIG. 6




FIG. 7




FIG. 8




FIG. 9

| | Clinical Decision Limit mean + 2SD |
|-------------|---------------------------------------|
| Sensitivity | 77 % |
| Specificity | 95 % |
| PPV | 94 % |
| NPV | 82 % |
| LR | 14.8 |

FIG. 10

| Marker | Sensitivity |
|-----------------------------------------|-------------|
| MBP IgG + Tm | 93 % |
| MBP IgG + MBP | 90 % |
| Tm + MBP | 77 % |
| All three markers MBP IgG + MBP + Tm | 95 % |